Researchers focused on a pathway that harnesses reactive oxygen species (ROS) to kill cancer cells. The study found that mutations to VPS35, a key player in this pathway, can prevent ...

In a major step forward for cancer treatment, researchers have developed a new type of “smart” chemical that attacks ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Cracking the Code of Melanoma's Drug Escape Melanoma, the deadliest form of skin cancer, is often driven ... linked SFK activation to reactive oxygen species (ROS), a cellular stress response ...

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

Researchers focused on a pathway that harnesses reactive oxygen species (ROS) to kill cancer cells. The study ...

has been cleared for patients with ROS1-positive non-small-cell lung cancer (NSCLC) on the back of overall response rate (ORR) data from the phase 1/2 TRIDENT-1 study after a priority review by ...